Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07495852 · ClinicalTrials.gov registry record · Phase 3
Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
A Phase 3 study, sponsored by Glaukos Corporation.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 510
- Enrollment target
NCT07495852 is a Phase 3 study that is actively recruiting participants, run by Glaukos Corporation. The registered enrollment target is 510 participants.
The verdict
NCT07495852, a Phase 3 study, is actively recruiting participants, sponsored by Glaukos Corporation.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 510 participants
- Enrollment target
Study Summary
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Interventions
- PROCEDURE Sham Procedure
- DRUG Gen 2 Travoprost Intracameral Implant
- DRUG Timolol eye drops 0.5%
- OTHER placebo eye drops
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 510 participants |
| Start Date | 2026-02-17 |
| Est. Completion | 2032-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07495852
The ClinicalTrials.gov registry entry for NCT07495852 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 510 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glaukos Corporation, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Sham Procedure is the first listed.
NCT07495852 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07495852 about?
NCT07495852 is a clinical study titled "Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant". Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
What is the current status of trial NCT07495852?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 510 participants. The study started on 2026-02-17. Estimated completion is 2032-03.
What interventions are being tested in trial NCT07495852?
The interventions under investigation include: Sham Procedure (PROCEDURE), Gen 2 Travoprost Intracameral Implant (DRUG), Timolol eye drops 0.5% (DRUG), placebo eye drops (OTHER).
Who is sponsoring clinical trial NCT07495852?
This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.